The post GRT Weekly Analysis Feb 28 appeared on BitcoinEthereumNews.com. GRT closed the week with a 7.69% decline, attempting to form a weak base at $0.02; howeverThe post GRT Weekly Analysis Feb 28 appeared on BitcoinEthereumNews.com. GRT closed the week with a 7.69% decline, attempting to form a weak base at $0.02; however

GRT Weekly Analysis Feb 28

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

GRT closed the week with a 7.69% decline, attempting to form a weak base at $0.02; however, the $0.0226 support remains critical as long as the main downtrend structure is not broken. Bitcoin’s bearish supertrend signal is increasing pressure on altcoins, while the positive histogram on MACD gives hope for short-term recovery.

GRT in the Weekly Market Summary

GRT is showing consolidation squeezed in the $0.02-$0.03 range on a weekly basis, but the overall market structure maintains its downtrend character. While the price moves sideways around $0.02, the volume profile remains low at $9.66M, with limited buyer interest. RSI at 36.35 is approaching the oversold region, and the MACD histogram shows a positive divergence, signaling a potential momentum shift. This week, Bitcoin’s weakness below $64K put extra pressure on GRT; for position traders, the main focus should be on the integrity of the trend structure and whether key supports hold. For more detailed spot data, check the GRT detailed spot analysis page.

Trend Structure and Market Phases

Long-Term Trend Analysis

The long-term trend structure indicates a clear downtrend on higher timeframes (1W and 3M); the price remains below the EMA20 ($0.03) and EMA50 ($0.035) averages. Market structure is characterized by lower highs and lower lows, with a pullback of up to 52% from the $0.0421 peak in recent months. This phase reflects a classic correction stage after distribution; however, the divergence on RSI indicates trend fatigue, implying a potential reversal setup. From a portfolio manager perspective, long positions are risky as long as the downtrend remains intact; the real opportunity lies in a breakout with confluence.

Accumulation/Distribution Analysis

Market phase analysis shows dominant distribution patterns on the weekly chart: High-volume sales have rejected above $0.03, but volume clusters around $0.0226 are giving accumulation signals. According to Wyckoff methodology, this range may be in the ‘spring test’ (support test) phase; if low-volume drops encourage buyers, a transition to accumulation phase is possible. The current low RSI and positive MACD histogram suggest that smart money has begun quiet accumulation, but rising BTC dominance could delay this scenario. For futures trading, follow GRT futures market data.

Multi-Timeframe Confluence

Daily Chart View

On the daily timeframe, the price is squeezed between 1 support ($0.0226) and 3 resistances ($0.0247, $0.0262, $0.03); bearish short-term MA alignment (below EMA20) reinforces the downtrend. A bullish MACD crossover is observed in momentum, but an oversold bounce is expected with RSI near 36. There are 9 strong level confluences: Bearish bias dominates on the daily, but if $0.0226 holds, a higher low formation may occur. Position traders should monitor daily closes to evaluate early entries.

Weekly Chart View

From a weekly perspective, the downtrend structure is clear: Price is below 1W Supertrend and facing major resistance from $0.0421. Strong 1 support ($0.0226) and 3 resistance confluence on 1W; weekly candles are seeking trend change with doji-like (indecisive) closes. Although the long-term filter is bearish, low activity in the volume profile signals accumulation preparation. This is a patience-requiring setup for monthly horizon traders; check the general market page for GRT and other analyses.

Critical Decision Points

Key inflection points are as follows: Support $0.0226 (68/100 score, multi-TF confluence), a break below opens $0.0139 downside risk. Resistances $0.0247 (88/100, strongest), $0.0262 (77/100), and $0.0421 (64/100); a weekly close above $0.0247 would question the trend structure. Upside objective $0.0347 (30 score), strategic R/R ratio calculable around 1:2.5. These levels will define direction; short bias is maintained if downtrend is not broken.

Weekly Strategy Recommendation

In Case of Rise

Bullish scenario: Long entry on $0.0247 breakout and weekly close above; first target $0.0262, extend to $0.0347. Stop-loss below $0.0226, R/R 1:3+. If MACD confirms bullish momentum confluence, transition to accumulation phase is validated; partial profit taking is recommended.

In Case of Fall

Bearish scenario: Short position on $0.0226 break; target $0.0139, stop above $0.0247. If downtrend structure remains intact, distribution continues; accelerates if BTC slips below $62K. Risk management is critical, position size 1-2%.

Bitcoin Correlation

GRT shows high correlation with BTC (%0.85+); BTC downtrend (below $64K) and bearish supertrend are increasing selling pressure on altcoins. If BTC key supports $62,569-$60K do not hold, GRT tests $0.0226; resistance above $64,340 brings relief to GRT (towards $0.0247). Rising BTC dominance crushes utility tokens like GRT; BTC levels to watch: $62K support and $66K resistance.

Conclusion: Key Points for Next Week

Next week focus: $0.0226 support test and $0.0247 breakout attempt; BTC break below $62K increases risks. If trend structure stays in downtrend, patience; scaled entry on bullish confluence. Monitor volume increase and RSI divergence; defensive positioning recommended while no altseason signal in macro cycle.

This analysis uses Chief Analyst Devrim Cacal’s market views and methodology.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/grt-technical-analysis-february-28-2026-weekly-strategy

Market Opportunity
Graph Token Logo
Graph Token Price(GRT)
$0.02551
$0.02551$0.02551
+0.35%
USD
Graph Token (GRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09